You are here

Home » Content

Bevakizumab ve Pegaptanip sodyum'un civciv koryoallantoik membrandaki in vivo anjiyogenez üzerine etkisi

The effects of Bevacizumab and Pegaptanip sodium on in vivo angiogenesis in chick chorioallantoic membrane

Journal Name:

  • Gülhane Tıp Dergisi

Publication Year:

  • 2008

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
The purpose of this study was to demonstrate the antiangiogenic efficacy of the two agents (Pegaptanip sodium and Bevacizumab), which are commonly used in the treatment of age-dependent macula degeneration in chick chorioallantoic membran model. Fertilized eggs obtained from Atak-S type chicken were used. The eggs were kept under appropriate heat and humidity until the fifth day on when the application would be performed. Pegaptanip sodium and Bevacizumab were applied to eggs at different concentrations, and the eggs were kept under an appropriate condition until the evaluation of the results. Results were evaluated at the 48th hour after application. Although both of the two agents have affirmative effects on age-dependent macula degeneration in humans, they did not have any antiangiogenic effects in chick chorioallantoic membran model. These findings may have resulted from inadequate doses of drugs chosen or from different features of human and chick vascular endothelial growth factor isoforms, and thus, more detailed studies are needed to perform.
Bookmark/Search this post with
Abstract (Original Language): 
Bu çalışmanın amacı, yaşa bağlı maküla dejenerasyonunun tedavisinde sıkça kullanılan iki preparatın (Pegaptanip sodyum ve Bevakizumab) anti-anjiyojenik etkinliğini civciv koryoallantoik membran modelinde göstermektir. Çalışmada, Atak-S cinsi tavuklardan alınan döllenmiş yumurtalar kullanıldı. Yumurtalar uygun nem ve sıcaklık şartları altında uygulamanın yapılacağı 5. güne kadar bekletildi. Daha sonra Pegaptanip sodyum ve Bevakizumab'ın farklı konsantrasyonları yumurtalara uygulandı ve sonuçlar değerlendirilinceye kadar uygun koşullarda saklandı. Sonuçlar, uygulama sonrası 48. saatte değerlendirildi. Her iki ilacın da insanlarda yaşa bağlı maküla dejenerasyonundaki olumlu etkilerine rağmen, civciv koryoallantoik membran modelinde anti-anjiyojenik etkileri gözlenmedi. Bu sonuçların seçilen ilaç dozlarının yetersizliğinden veya insan ve civciv damar endotelinin büyüme faktörü izoformlarının farklı özelliklerinden kaynaklanmış olabileceği düşünülmüş ve bu nedenle daha detaylı çalışmalara ihtiyaç olduğu sonucuna varılmıştır.
FULL TEXT (PDF): 
PDF icon arastirmax-bevakizumab-pegaptanip-sodyumun-civciv-koryoallantoik-membrandaki-vivo-anjiyogenez-uzerine-etkisi.pdf
  • 1
19-22
  • Turkish

REFERENCES

References: 

1. Costa C, Soares R, Schmitt F. Angiogenesis: now and
then. APMIS 2004; 112: 402-412.
2. Ribatti D, Vacca A, Presta M. The discovery of angiogenic
factors: a historical review. Gen Pharmacol 2002; 35: 227-
231.
3. Norrby K. In-vivo models of angiogenesis. J Cell Mol
Med 2006; 10: 588-612.
4. Ng EW, Shima DT, Calias P, Cunnigham ET Jr, Guyer
DR, Adamis AP. Pegaptanib, a targeted anti-VEGF
aptamer for ocular vascular disease. Nat Rev Drug Discov
2006; 5: 123-132.
5. Eyetech Study Group. Preclinical and phase 1A clinical
evaluation of an anti-VEGF pegylated aptamer (EYE001)
for the treatment of exudative age-related macular degeneration. Retina 2002; 22: 143-152.
6. Ribatti D, Vacca A, Roncali L, Dammacco F. The chick
embryo chorioallantoic membrane as a model for in vivo
research on angiogenesis. Int J Dev Biol 1996; 40: 1189-
1197.
7. Kaiser PK. Antivascular endothelial growth factor agents
and their development: therapeutic implications in ocular
disease. Am J Ophtalmol 2006; 142: 660-668.
8. Leung DW, Cachianes G, Kuang WJ, Goeddel DV,
Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-1309.
9. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung
DW. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991;
5: 1806-1814.
10. Lei J, Jiang A, Pei D. Identification and characterization of
a new splicing variant of vascular endothelial growth factor: VEGF183. Biochim Biophys Acta 1998; 1443: 400-
406.
11. Tolentino MJ, Miller JW, Gragoudas ES, Chatzistefanou
K, Ferrara N, Adamis AP. Vascular endothelial growth
factor is sufficient to produce iris neovascularization and
neovascular glaucoma in a nonhuman primate. Arch
Opthalmol 1996; 114: 964-970.
12. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong22 · Mart 2008 · Gülhane TD Durukan ve ark.
PT. Increased expression of angiogenic growth factors in
age-related maculopathy. Br J Opthalmol 1997; 81: 154-
162.
13. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal
fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest
Opthalmol Vis Sci 1996; 37: 1929-1934.
14. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod
M, Guyer DR: VEGF Inhibition Study in Ocular
Neovascularization Clinical Trial Group. Pegaptanip for
neovascular age-related macular degeneration. N Engl J
Med 2004; 351: 2805-2816.
15. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN,
Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration:
twelve-week results of an uncontrolled open-label clinical
study. Ophthalmology 2005; 112: 1035-1047.
16. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical
coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related
macular degeneration. Ophthalmic Surg Lasers Imaging
2005; 36: 331-335.

Thank you for copying data from http://www.arastirmax.com